Research has demonstrated that β‐AR blockade enhances immunotherapy efficacy by regulating immune responses, and preclinical studies across various cancers suggest that inhibiting adrenergic signaling can improve anti‐tumor immune effects. This evidence concerns the gene ADRB2 and neoplasm.